Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a single arm, multi-centre (via Big Ten Cancer Research Consortium) phase Ib/II study
of patients treated with durvalumab 1500 mg IV q 4 weeks in combination with guadecitabine at
the recommended phase 2 dose subcutaneously for 5 consecutive days. Eligible patients will
have metastatic RCC with a clear cell component, ECOG performance status of 0-1, have
received 0-1 prior therapy but no prior anti-PD-1/PD-L1/CTLA4 (Cohort 1, 36 subjects). Study
treatment could potentially continue for up to 13 cycles (52 weeks).